Leukocare AG participated in the Antibody CMC Development Xchange in San Francisco, where a roundtable explored molecular properties and computational approaches for antibody CMC development.
Public source
Publisher name
Public post
At the Antibody CMC Development Xchange in San Francisco, our roundtable focused on one practical question: 𝗛𝗼𝘄 𝗰𝗮𝗻 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗮𝗻𝗱 𝗰𝗼𝗺𝗽𝘂𝘁𝗮𝘁𝗶𝗼�…
Company
Leukocare AG
Experts in Sterile Drug Product Formulation Services
- Industry
- Biotechnology Research
- Location
- Planegg, DE
- Company size
- 51–200 employees
About Leukocare AG
For over 20 years, Leukocare has been trusted by pharmaceutical companies, mid-sized biotech firms, and innovative biotechs for our Quality by Design-driven approach to formulation development. Our proven track record includes advancing companies into clinics, filing BLAs, and enabling patent potential, demonstrating our commitment to the successful development of cutting-edge therapies. Our strength lies in combining strong formulation expertise with data science and statistical approaches, ensuring a systematic, evidence-driven path forward. With extensive experience in both liquid and lyophilized formulation development for proteins, monoclonal antibodies (mAbs), viral vectors, and viruses, we are equipped to tackle the most complex challenges combining 100+ regulatory approved excipients. However, our greatest asset is our adaptability. We remain agile, responding quickly to changes in the regulatory landscape and evolving client needs. By combining scientific expertise with a deep understanding of regulatory requirements and the latest industry advancements, we ensure that our clients are always a step ahead. Typical projects include: • Molecular Modeling and Benchmarking • Pre-Formulation • QbD Formulation Development and Optimization • Process Development and Transfer • IP Support We believe that a great formulation is not just about scientific knowledge; it’s about relevant data, an in-depth understanding of regulatory and industry standards, and the ability to adapt quickly to the changing landscape of drug development. Let’s connect to explore how we can help advance your drug product developments. You can reach out by: • Messaging us on LinkedIn to start a conversation. • Visiting our website to learn more about our services and get in touch with our team. • Emailing us directly at info@leukocare.com for personalized support.
See moreLatest activity
Latest activity from Leukocare AG
6 signals
Presence & Recognition
Leukocare AG employee Dr. Estefania Vidal will be speaking at DDF Boston on the topic of predictive approaches in formulation and CMC.
Presence & Recognition
Leukocare AG is hosting a roundtable meeting at DDF in Boston on September 14–15.
Presence & Recognition
Leukocare AG hosted a roundtable titled From Data to Decisions: Computational Strategies for De-Risking Drug Product Development at HubXchange in San Francisco.
Discover more
Similar signals
Similar public activity from other companies.
Presence & Recognition
Biotech Targeting
Biotech Targeting hosted the Securing Sterile Injectable Supply Executive Summit at Curia's Albuquerque facility bringing together CMC, Tech Ops, and Supply Chain leaders from across pharma and biotech.
Presence & Recognition
ProBioGen AG
ProBioGen AG is hosting a meeting with Xiao-Ping Dai, Ph.D. and Dr. Ellen Hilgenberg on September 10 to discuss building stage-appropriate CMC strategy and reducing downstream risk.
Presence & Recognition
Sartorius | Bioprocess Solutions
Sartorius | Bioprocess Solutions hosted a roundtable discussion to explore how the bioprocessing industry can respond to evolving regulations for fill and finish.
Presence & Recognition
Generare
Generare is hosting the International Symposium on Medicinal Chemistry on behalf of the EFMC - European Federation for Medicinal Chemistry and Chemical Biology in Basel next week.
Presence & Recognition
PROTEROS biostructures GmbH